Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing ...

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening disease. Intellia expects to complete ...

The pipeline candidate, NTLA-2002, is designed to inactivate a gene involved in potentially life-threatening inflammatory attacks for people suffering from this rare disorder. In the ongoing phase ...

Reduction of 75 and 77% seen in estimated mean monthly attack rate with 25-, 50mg NTLA-2002 vs placebo. HealthDay News — For adults with hereditary angioedema, the in vivo gene-editing therapy ...